Published Paper Details:

Abstract: The therapeutic potential of Syzygium cumini (black plum or Jamun) seed powder (JSP) in managing type 2 diabetes mellitus (T2DM) is widely recognized in traditional medicine, largely attributed to its rich phytochemical composition of polyphenols, flavonoids, and tannins. These compounds confer a range of benefits. Mechanistically, JSP appears to exert its effects through multifaceted pathways: it can stimulate insulin secretion from pancreatic beta-cells, improve peripheral insulin sensitivity, inhibit key carbohydrate-digesting enzymes (like alpha-amylase and alpha-glucosidase), and actively mitigate oxidative stress-induced beta-cell damage via its significant antioxidant capacity. A review of available clinical evidence indicates that limited human studies support these preclinical findings. Trials have reported promising outcomes, including notable reductions in both fasting and postprandial blood glucose levels in T2DM patients. Furthermore, JSP consumption has been associated with improved lipid profiles, addressing the common comorbidity of dyslipidemia. While these results suggest significant potential as a complementary therapy, the existing clinical data remains sparse. Further rigorous, large-scale, and well-controlled clinical trials are imperative to standardize the effective dosage, establish long-term efficacy, and confirm safety across diverse patient populations.